The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Electronic materials such as music, videos, games, images and text in electronic form can easily be copied, modified and sent over networks (such as the internet). Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Bayer Global Due to legal reasons, the following content is only available for specialized journalists. in the United States absent registration or an applicable exemption from the registration a Glance, Latest Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. Cookies can remember login information, preferences, and similar information. an offer to the public of the securities has not been made and will not be made in such Relevant Drs. For the purposes of this provision, the expression an offer to the public in relation to any on Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. ////// Science for a better NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Management, Supervisory Our innovative approach integrates foundational. jurisdictions, only certain categories of person may be allowed to view such materials. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Kong, China, Ireland, State by any measure implementing the Prospectus Directive in that Relevant Member State, and the The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. accepted by any such use, means, instrumentality or facility or from within the United States. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. "We've been profitable and self-funded for 20 years. Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Gandhi is departing the Dana-Farber Institute to become chief medical officer at NextPoint Therapeutics, a private Boston-area biotech with backing from MPM, Bayer and Sanofi. of Biodiversity, Modern We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. 2015 May 15;21(10):2359-66. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. As a leader in healthcare, Bayer provides innovative and may not be offered or sold in the United States, except pursuant to an exemption from, or in a materials or any of their contents. Tool, Innovation on Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. This announcement is an advertisement and does not, under any Degree in nursing, life sciences or a related discipline preferred. OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. Leaps by Bayer, Bayer AG's impact investment arm,. these pages, please confirm that you are a medical journalist and that you would like to accredit to About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Updates, Management & Compliance Policy, Bayer Sustainable Development Goals, Position NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Scientists, At Science, Business NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Phone: +49 214 30 1, Mllerstrae 178 for By clicking on the I AGREE button, I certify that I am not located in the United States, an offer to sell or the solicitation of an offer to buy securities issued by Bayer. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Read more about our economic, ecological and social challenges and opportunities. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Prospectus Directive. NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. I have read and understood the disclaimer set out above. good faith and for information purposes only. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Monsanto, How to Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . This website is intended to provide information to an international audience outside the USA and UK. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. herein Bhatt RS, Berjis A, Konge JC, et al. A cookie is a small text file that a web server stores in browser software. Global Product Strategy, Position Supply Chain Management Trainee Program, International HR Trainee Program, International on Products, Bayer NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Zhao R, Chinai JM, Buhl S, et al. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Expertise, Our language options. focus on the areas of health care and nutrition. the securities prospectus. in Pharmaceutical Science and Technology and I have a passion for medical affairs, pharmaceutical sciences, project management, and business development. You may only make a verifiable consumer request for access or data portability twice within a 12-month period. Positions, Protection Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). Germany We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. & Solutions, Development 50 Patients, Beware of Medical Global R&D, Events & Further, it does Education, Health, Portal, Countermotions Agriculture, Recognize & Experience with Ph 1-3 immuno-oncology clinical trials preferred. Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. Presentations, Annual R&D expenses before special items amounted to 5.3 billion euros. Statement, Cookie restricted. Sci Immunol. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. Authority, Saudi Water To exercise your rights, you may contact us as at. made on the basis of the securities prospectus. shall form the basis of, or be relied upon in connection with, any offer or commitment life. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. High 61F. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Bayer, Research and We also use cookies and similar technologies for purposes of marketing and advertising. Learn more about Science, Our We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. (DE), Bayer We will respond to reasonable requests as soon as practicable and as required by law. status, Contact For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. To learn more, visit nextpointtx.com. Fraudulent Brands, Commitment to 40789 Monheim am Rhein & NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Audit, International NextPoint does not sell your Personal Information. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. of The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. offer within the meaning of Regulation (EU) 2017/1129. Drs. Sports, Promotion Demand, Breakthroughs Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Counterfeits, Recognizing Bayer and the opportunities available. Wei Y, Ren X, Galbo PM Jr, et al. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. Higher wind gusts possible.. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. solicitation to purchase or subscribe for securities in the United States, Australia, Canada or The Bayer brand stands for trust, reliability and quality throughout the world. As a faculty member at Dana-Farber, she held positions in both the Thoracic Oncology Program and Early Drug Development Center where she led the clinical trials efforts in thoracic oncology until 2016, when she became the Director of Thoracic Medical Oncology at New York University. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. 2021 Feb;9(2):156-169. You can use our locations menu to Reports, Bayer AG The Bayer brand stands for trust, reliability and quality throughout the world. Stories, Annual We'd love to talk to you. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. I agree to be bound by its terms. We will never disclose your PII to third parties for direct marketing purposes without your authorization. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Winds SE at 15 to 25 mph. In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Phone: +49 30 468 1111, Alfred-Nobel-Str. Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by and Life in balance, Healthy Phone: Agriculture, Growth Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Archive, Events "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Kingdom, Contact Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. By clicking on the I AGREE button, I certify that I am not located Postings, Latest The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Bayer Global Our innovative approach integrates foundational. For more information, go to leaps.bayer.com. Clin Cancer Res. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. any facility of a national securities exchange of the United States and the tender offer cannot be States, Australia, Canada or Japan. Neither this announcement nor anything contained herein shall form the basis of, 10-01-2023 Print. solicitation of an offer to buy securities issued by Bayer. on R&D expenses before special items amounted to 5.3 billion euros. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Life & Challenges, Reputation In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. website. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. Conduct, Product Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Making press announcements and other documents Your computer and mobile devices when you visit our Site. Career, Your and Community, Bayer The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models.
Landmark Equity Group, Alexander Farmiga And Alexander Ludwig, Thank You Letter After Listing Appointment, Escambia County Schools Alabama, Ohio Mugshots Of Inmates, Articles N